Despite a high incidence of adverse events, adding aflibercept to FOLFIRI chemotherapy is associated with “a consistent trend” of increased survival among metastatic colorectal cancer patients, regardless of patients’ previous bevacizumab treatment status, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Adding procarbazine, lomustine and vincristine chemotherapy to radiotherapy increases PFS and OS in patients with anaplastic oligodendroglial tumors and represents a new standard of care in those with 1p/19q co-deletions, according to data presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck did not improve OS, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Adding perifosine to capecitabine does not prolong overall survival in refractory metastatic colorectal cancer, according to results of phase 3 study reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Axitinib is effective in the first-line treatment of metastatic renal cell carcinoma, according to a study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Regorafenib prolongs PFS and OS in metastatic colorectal cancer that has progressed after all approved standard therapies, according to the phase 3 CORRECT trial presented at the 2012 American Society of Clinical Oncology Annual Meeting.
The experimental agent trastuzumab emtansine (T-DM1) offers significant and “clinically meaningful” improvement in PFS in some patients with HER2+locally advanced or metastatic breast cancer, according to a phase 3 study prestented at the 2012 American Society of Clinical Oncology Annual Meeting.
Patients with anaplastic oligodendroglioma with co-deletion for chromosomes 1p and 19q survive significantly longer after receiving chemotherapy immediately prior to radiotherapy, according to long-term follow-up of a randomized phase 3 study presented at the 2012 American Society of Clinical Oncology Annual Meeting.
Patients with annual household incomes below $50,000 vs over $50,000 were less likely to participate in clinical trials, according to results of a large national survey of people with cancer reported at the 2012 American Society of Clinical Oncology Annual Meeting.
Updated safety data has confirmed the overall safety profile observed in patients with platinum-sensitive recurrent ovarian cancer in the randomized phase 3 OCEANS trial, according to a study reported during the 2012 American Society of Clinical Oncology Annual Meeting.
Please login or register first to view this content.
